LETTER TO THE EDITOR OPEN ACCESS

Revumenib as A New Therapeutic Intervention for Relapsed or Refractory KMT2A-Rearranged Acute Lymphoblastic Leukemia

Khushbakht Baloch [1], ***Muniba Shoaib*** [2], ***Mishal Fatima*** [1]

[1]2nd Year MBBS Student, Jinnah Sindh Medical University, Karachi, [2]2nd Year MBBS Student, Ziauddin University, Karachi, Pakistan.

Doi: https://doi.org/10.36283/ziun-pjmd14-2/076

How to cite: Baloch K, Shoaib M, Fatima M Revumenib as A New Therapeutic Intervention for Relapsed or Refractory KMT2A Rearranged Acute Lymphoblastic Leukemia. Pak J Med Dent. 2025 April;14(2): 550-551. Doi: https://doi.org/10.36283/ziun-pjmd14-2/076.

Received: Wed, February 19, 2024 **Accepted:** Wed, March 26, 2025 **Published:** Sun, April 13, 2025

Dear Editor,

KMT2A (MLL)-rearranged acute lymphoblastic leukemia (ALL) is one of the most severe forms of leukemia that corresponds with high mortality, especially in relapsed or refractory cases. ALL affects both adults and children, thereby necessitating the need for treatment options that provide higher efficacy and reduce the high morbidity rate. Although many interventions have been introduced, the Survival rate is significantly low, emphasizing the need for new therapeutic strategies to treat ALL[1].

Revumenib is a menin inhibitor that has emerged as an efficient treatment for KMT2A (MLL)- rearranged acute lymphoblastic leukemia (ALL), as it inhibits the fusion of menin with KMT2A protein. Thus, it acts as a promising leukemogenesis inhibitor. Its efficacy has been shown by recent clinical trials, with substantial improvements seen in patients with relapsed or refractory KMT2A-rearranged ALL. According to an expansion study of Revumenib conducted across 22 clinical sites in five countries, treatment with the Menin inhibitor Revumenib provided clinical benefit and a predictable safety factor[2]. According to a recent review reported that revumenib was an exemplary targeted therapy for patients with relapsed or refractory KMT2A-r and NPM1-m leukemia[3]. Another systematic review declared Revumenib has significant clinical ramifications and serves as a helpful supplement to the treatment toolkit for KMT2A-rearranged ALL, given its potential to isolate the leukemic cells appropriately [4]. In addition to its potential as a stand-alone site therapy, multiple studies are being conducted where revumenib demonstrates high potential when utilized alongside additional medications, which potentially boosts its therapeutic value and makes it possible to use it as a stopgap measure before hematopoietic stem cell transplantation[5].

These strategies can greatly raise these patients' overall survival rates and quality of life. But there are still difficulties. Like many targeted medicines, revumenib resistance mechanisms require more research to guarantee long-term effectiveness. Additionally, controlling adverse effects and guaranteeing that this innovative treatment is accessible are important issues that need to be addressed. Its limited accessibility and expensive cost could avert broad implementation, especially in resource-constrained settings.

Additional studies on synergistic combination therapies and biomarker-driven patient stratification techniques would maximize Revumenib's effectiveness as a treatment. By enabling targeted interventions, this personalized medicine strategy will reduce needless treatment exposures and improve clinical results. The treatment of KMT2A-rearranged acute lymphoblastic leukemia (ALL) has advanced significantly with the introduction of revumenib. However, further research is necessary to completely understand its pharmacodynamic and pharmacokinetic characteristics, which will ultimately guarantee the best possible treatment outcomes and fair access for all eligible patient groups.

ACKNOWLEDGMENT
None

CONFLICT OF INTEREST
None

AUTHORS' CONTRIBUTIONS
All authors contributed equally.

REFERENCES
1. Forgione MO, McClure BJ, Eadie LN, Yeung DT, White DL. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Lett. 2020 Jan 28;469:410-418. doi: 10.1016/j.canlet.2019.11.005.
2. Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826.
3. Salman MY, Stein EM. Revumenib for patients with acute leukemia: a new tool for differentiation therapy. Haematologica. 2024 Aug 1;109(11):3488.doi: 10.3324/haematol.2022.282621
4. Jamil A, Qureshi Z, Siddique R, Kupakuwana-Suk G, Altaf F, Selene I. Efficacy and Safety of Revumenib in the Treatment of Acute Myeloid Leukemia with KMT2A Rearrangements or NPM1 Mutations: A Systematic Review. Blood. 2024 Nov 5;144:6065.doi: 10.1182/blood-2024-201875.
5. Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, McCall D, Pike A, Tan S, Kammerer B, Marshal A. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. Blood. 2024 Nov 5;144:216.doi:10.1182/blood-2024-204375.